Treatment of advanced or recurrent adenocarcinoma of the endometrium with doxorubicin and cyclophosphamide

Thirteen patients with recurrent or advanced endometrial carcinoma were treated with a combination of doxorubicin (40 mg/m ² IV) and cyclophosphamide (600 mg/m ² IV). All patients had been refractory to prior radiotherapy nd hormone therapy. None of the patients had received prior chemotherapy. Six of the 13 patients (46%) achieved an objective response: 1 complete response (8%) and 5 partial responses (38%). Median overall survival was 10 months (range 3-20 months). Doxorubicin and cyclophosphamide is an active combination in patients with advanced endometrial cancer.